'김갑성' 기자의 전체기사
-
ZeroAvia Completes Financing Round
KEMBLE, UK and EVERETT, Wash., Dec. 22, 2025 -- ZeroAvia today announced that it has completed a further round of financing, led by Barclays Climate Ventures, Breakthrough Energy Ventures, Ecosystem Integrity Fund, Horizons Ventures, Summa Equity, and AP Ventures, with participation from the National Wealth Fund and the Scottish National Investment Bank. With additional investment secured, ZeroAvia has extended its cash runway for the next two years and will continue to fully industrialize its hydrogen power and propulsion technology for the aviation and defense markets.
- 김갑성 기자
- 2025-12-22 13:00
-
The 8th Hainan International Health Industry Expo opens in…
HAIKOU, China, Dec. 22, 2025 -- A report from Hainan International Media Center: On December 20, 2025, the 8th Hainan International Health Industry Expo opened in Sanya. Coinciding with the crucial juncture of the Hainan Free Trade Port's island-wide special customs operations, this Expo serves as both a platform for Hainan to showcase achievements in the development of the health industry and as a window to envision the future of the health industry. This year's 4-day 12,000m² Expo has attracted 253 domestic and international companies to participate and covers innovative
- 김갑성 기자
- 2025-12-22 11:44
-
Wong To Yick Unveils Revitalised Official Website
Launching a New No.1 Brand Chapter with Ambassador Joey Yung Enhanced Authenticity Guidance & Usage Education for Elevated Consumer Confidence [High-resolution promotional photo download: Here] HONG KONG, Dec. 22, 2025 -- Wong To Yick, the iconic Hong Kong medicated balm brand trusted for over half a century, proudly unveils its newly upgraded official website, marking a significant milestone in the brand's global expansion journey. As the second major initiative under its brand upgrading programme, the new digital platform follows the earlier announcement
- 김갑성 기자
- 2025-12-22 09:00
-
Fosun International Honored with TVB's Highest Accolade, "…
HONG KONG, Dec. 22, 2025 -- On 19 December 2025, the TVB ESG Awards 2025 Presentation Ceremony, hosted by Television Broadcasts Limited ("TVB"), was held at the Hong Kong Convention and Exhibition Center. Fosun International was honored with the highest accolade, the "Outstanding ESG Award", as well as awards for "Best in ESG Practices" and "Best in ESG Report". Mr. Wong Wai Lun, Michael, GBS, JP, Deputy Financial Secretary of the Government of the Hong Kong Special Administrative Region (SAR), Mr. Siu Sai Wo, General Manager (Business Operations
- 김갑성 기자
- 2025-12-22 09:00
-
Precision Medicine Portfolio Update: Illuccix China Phase 3…
MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation to: TLX591-CDx (Illuccix® in approved jurisdictions, 68Ga-PSMA-11): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China. TLX101-CDx (Pixclara®[1], 18F-floretyrosine), PET imaging candidate for glioma: Following collaborative interactions with the FDA, finalizing NDA resubmission and expect to provide a f
- 김갑성 기자
- 2025-12-22 05:40
-
T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT02…
BEIJING, Dec. 21, 2025 -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial for the treatment of recurrent glioblastoma (rGBM). This milestone marks a significant breakthrough in addressing one of the most formidable challenges in oncology: developing effective allogeneic CAR-T therapies for solid tumors. "The FDA's clearance of the IND for MT027 represents a strong validation of our strategic commitment to tacklin
- 김갑성 기자
- 2025-12-21 20:20
-
Jacobio Pharma Enters Global Exclusive License Agreemen…
BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive exclusive development and commercialisation rights outside of China, while Jacobio and AstraZeneca will jointly develop and commercialise JAB-23E73 in China. Under the terms of the agreement, Jacobio will receive an upfront payment of US$100 million, and is eligible for additional development and commercial milestone payments of up to US$1.915 billion, as well as tiered royal
- 김갑성 기자
- 2025-12-21 20:15
-
Alphamab Oncology Announces Biparatopic HER2-targeting…
SUZHOU, China, Dec. 20, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), has been granted breakthrough therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal, or fallopian tube c
- 김갑성 기자
- 2025-12-20 12:54
-
Gene Solutions Concludes Successful ESMO Asia Congres…
SINGAPORE, Dec. 20, 2025 -- Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology (ESMO) Asia Congress 2025—held in Singapore on December 5–7. Highlights included a full-house symposium, seven scientific abstracts with two earning Best Poster designations, and meaningful engagement with thousands of oncologists from across the Asia-Pacific region at the company's exhibition booth. 2025 has marked a year of substantial progress for Gene Solutions, with expanded presence and partnerships across India, Turkey, Taiwan
- 김갑성 기자
- 2025-12-20 11:14
-
Ceretone Showcases Core One Pro -- The Nearly Invisible OT…
[ 메디채널 김갑성 기자 ] Ceretone invites CES attendees to experience its latest penny-sized, feather-light hearing solution and complimentary hearing tests at Booth #54619 LAS VEGAS, Dec. 20, 2025 -- Ceretone, a consumer health technology company dedicated to making quality hearing solutions accessible and affordable, announces its participation at the Consumer Electronics Show (CES) 2026 in Las Vegas, Nevada, from January 6–9, 2026. At Booth #54619 in the Venetian Campus, Halls A-D, Ceretone will showcase its newest product, the Core One Pro, a next-generation OTC hearing aid designe
- 김갑성 기자
- 2025-12-20 02:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 5하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 6대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 7만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2026-01-31_SAT
- Sanyou Bio's Decade: From an Intelligent Super-Trillion Antibody Library to the "Innovation Hub for Original Drug Discovery" 16:15
- CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK 12:05
- Origin Agritech Announces Fiscal Year 2025 Results 06:00
- White Pearl Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering 05:47
- Planet Green Holdings Corp. Provides Response to Unusual Market Action 05:05
- SKF completes previously announced divestment of non-core aerospace operation in Elgin, USA 03:36
- DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion 03:34
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2026년 01월 31일 17시 40분